Why this has not been done

Everyone who could build this has a reason not to.

Manufacturers

Build the medicine and the manufacturing. Their economic interest is in more delivery sites, not fewer. A counterparty, not a competitor.

Academic cancer centres

Hold most of the current administration capacity, run waiting lists, and do not expand into secondary metropolitan areas.

Hospital systems

A shielded hot laboratory competes for capital against a surgical robot on the same committee, and radiopharmacy is treated as a cost centre rather than a service line.

Freestanding operators

A small number run two to four centres each. They prove the model works and they are subscale.

Imaging platforms

Own the scanners. They do not hold a licence for unsealed therapeutic material and do not employ an Authorised User.